• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $LMAT alert in real time by email

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board.

    Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatment of peripheral vascular disease, from 2007 through March 7, 2025, and continues to serve as a member of their Board of Directors. Mr. Pellegrino joined LeMaitre Vascular as their Executive Vice President, Finance, in 2005. From 1997 to 2003, Mr. Pellegrino worked at Zoots, Inc., a consumer services company founded by the founders of Staples, Inc., where most recently he served as Senior Vice President of Operations. Previously, Mr. Pellegrino built and sold a regional mall-based specialty retailing company. Mr. Pellegrino has also served as an investment banking analyst at Lehman Brothers, as part of their mergers and acquisitions group. From 2017 to 2024, Mr. Pellegrino was a director of Access Vascular, Inc., a medical device company focused on venous access devices. Mr. Pellegrino received an A.B. in Economics from Harvard College and an M.B.A. from the Harvard Business School.

    "We are excited to have JJ Pellegrino join the Precision Optics Board of Directors," said Peter Woodward, Chairman of the Board of Precision Optics. "As a highly accomplished financial executive in the medical device industry, JJ infuses strategic financial leadership, operational discipline, and deep industry insights to the board to help drive sustainable growth, regulatory foresight, and scalable innovation. His record of success in building a company from early beginnings to significant scale and shareholder appreciation are directly relevant to us at Precision Optics."

    In connection with Mr. Pellegrino's appointment, Peter Anania has retired from the Board of Directors. Mr. Anania was initially appointed to Precision Optics' Board in October 2021 in connection with the acquisition of Lighthouse Imaging. Mr. Anania was Lighthouse Imaging's President and Chairman at the time of the acquisition.

    "I want to thank Peter for his many contributions to the POC board. He was a great resource following the Lighthouse acquisition and has been a strong contributor since. We wish him well in the future," Mr. Woodward stated.

    About Precision Optics Corporation

    Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics, 3D imaging and digital imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume worldwide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top-tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power. For more information, please visit www.poci.com.

    About Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on certain assumptions and analyses made by the management of the Company in light of their respective experience and perception of historical trends, current conditions, and expected future developments and their potential effects on the Company as well as other factors they believe are appropriate in the circumstances. There can be no assurance that future developments affecting the Company will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, including risks that the closing conditions for this offering will not be achieved, the demand for the Company's products, global supply chains and economic activity in general and other risks and uncertainties identified in the Company's filings with the SEC. Should one or more of these risks or uncertainties materialize or should any of the assumptions being made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

    Company Contact:

    PRECISION OPTICS CORPORATION

    22 East Broadway

    Gardner, Massachusetts 01440-3338

    Telephone: 978-630-1800

    Investor Contact:

    LYTHAM PARTNERS, LLC

    Robert Blum

    Telephone: 602-889-9700

    [email protected]



    Primary Logo

    Get the next $LMAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMAT
    $POCI

    CompanyDatePrice TargetRatingAnalyst
    LeMaitre Vascular Inc.
    $LMAT
    2/28/2025Outperform → Perform
    Oppenheimer
    LeMaitre Vascular Inc.
    $LMAT
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    LeMaitre Vascular Inc.
    $LMAT
    2/13/2025$95.00Equal Weight
    Wells Fargo
    LeMaitre Vascular Inc.
    $LMAT
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    LeMaitre Vascular Inc.
    $LMAT
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    LeMaitre Vascular Inc.
    $LMAT
    5/31/2024$100.00Buy
    ROTH MKM
    LeMaitre Vascular Inc.
    $LMAT
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    LeMaitre Vascular Inc.
    $LMAT
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $LMAT
    $POCI
    SEC Filings

    See more
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/20/25 4:15:10 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/19/25 4:30:09 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Precision Optics Corporation Inc.

      10-Q - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/15/25 4:15:46 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LMAT
    $POCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lemaitre Vascular downgraded by Oppenheimer

      Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

      2/28/25 8:28:09 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Lemaitre Vascular downgraded by Barrington Research

      Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

      2/28/25 7:39:54 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Lemaitre Vascular with a new price target

      Wells Fargo initiated coverage of Lemaitre Vascular with a rating of Equal Weight and set a new price target of $95.00

      2/13/25 7:09:15 AM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman and CEO Lemaitre George W sold $8,556,631 worth of shares (100,000 units at $85.57) and exercised 34,619 shares at a strike of $44.64, decreasing direct ownership by 3% to 1,827,003 units (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/20/25 7:11:24 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      5/20/25 4:15:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Ross Bridget A sold $312,000 worth of shares (3,750 units at $83.20) and exercised 3,750 shares at a strike of $30.00 (SEC Form 4)

      4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

      5/14/25 4:03:49 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    $POCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

      GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

      3/4/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

      GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

      7/8/24 9:00:00 AM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LMAT
    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:31 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:30 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:33 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $LMAT
    $POCI
    Financials

    Live finance-specific insights

    See more
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LeMaitre Q1 2025 Financial Results

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

      5/1/25 4:05:32 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025

      BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and ser

      4/7/25 3:56:16 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

      GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025. Q3 2025 Financial Highlights (3 Months Ended March 31, 2025): Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $

      5/15/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference

      BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre

      5/5/25 4:39:09 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care

    $LMAT
    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

      SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      11/13/24 5:53:45 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by LeMaitre Vascular Inc.

      SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

      10/22/24 3:49:21 PM ET
      $LMAT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Precision Optics Corporation Inc.

      SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      5/17/24 5:03:18 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care